Armata Pharmaceuticals (ARMP) Enterprise Value (2013 - 2026)

Armata Pharmaceuticals has disclosed Enterprise Value across 14 years of filings, most recently posting -$4.8 million for Q1 2026.

• Enterprise Value for Q1 2026 came in at -$4.8 million, up 59.33% year-over-year; the trailing twelve-month figure through Mar 2026 was -$4.8 million (up 59.33% YoY), and the FY2025 annual result was -$8.7 million, up 6.49% from the prior year.
• Enterprise Value came in at -$4.8 million for Q1 2026 at Armata Pharmaceuticals, up from -$8.7 million in the prior quarter.
• In the past five years, Enterprise Value ranged from a high of -$4.3 million in Q2 2025 to a low of -$46.4 million in Q1 2022.
• The 5-year median for Enterprise Value is -$14.9 million (2022), against an average of -$19.6 million.
• Across the five-year window, Enterprise Value plunged 111.99% in 2024 and surged 83.72% in 2025, its largest moves.
• Armata Pharmaceuticals' Enterprise Value stood at -$14.9 million in 2022, then grew by 8.95% to -$13.5 million in 2023, then jumped by 31.29% to -$9.3 million in 2024, then climbed by 6.49% to -$8.7 million in 2025, then soared by 45.28% to -$4.8 million in 2026.
• The last three Enterprise Value figures came in at -$4.8 million (Q1 2026), -$8.7 million (Q4 2025), and -$14.8 million (Q3 2025), per Business Quant data.